Chimeric Norovirus Capsid Proteins for Broad Strain Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development for noroviruses is hindered by the complex antigenic relationships among numerous strains and the rapid antigenic variation of the virus, which makes it difficult to achieve broad protection against multiple strains.
Innovation Solution
The development of chimeric norovirus capsid proteins and virus-like particles (VLPs) that incorporate specific blockade epitopes from different strains, allowing for the induction of a broadly blocking immune response by presenting these epitopes on a synthetic backbone or surface, thereby overcoming antigenic variation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional vaccine approaches targeting single norovirus strains are used, then immunity against that specific strain is achieved, but protection against other antigenically distinct strains is insufficient
Solution Approach 1:
The vaccine composition uses a conserved capsid protein backbone that is universally recognized across multiple norovirus strains, allowing a single vaccine formulation to provide protection against diverse strains including GII.4, GII.17, and other genotypes. The backbone serves multiple functions by presenting conserved epitopes that elicit cross-strain neutralizing antibodies.
Solution Approach 2:
The invention creates a composite antigen structure by fusing conserved backbone sequences from multiple norovirus strains into a single chimeric capsid protein. This composite approach combines protective elements from different strains while maintaining structural integrity, resulting in enhanced cross-protection compared to single-strain vaccines.
2Reliability
If the vaccine targets highly variable epitopes to achieve strain-specific protection, then immunity against that strain is strong, but the vaccine becomes ineffective against antigenically distinct strains
Solution Approach 1:
The vaccine design applies local quality by selectively incorporating conserved regions from the norovirus capsid protein while excluding highly variable regions. Specifically, the backbone sequences are chosen to maintain structural integrity and present conserved neutralizing epitopes, while variable domains are minimized or standardized across different strain combinations.
3Adaptability or versatility
If a multivalent vaccine containing multiple whole virus particles is used to achieve broad protection, then coverage against multiple strains is improved, but the complexity of formulation and manufacturing increases
Solution Approach 1:
The invention merges protective epitopes from multiple norovirus strains into a single chimeric capsid protein construct. This consolidation approach combines the advantages of multivalent vaccination (broad protection) with the simplicity of monovalent formulation, eliminating the need for separate vaccine formulations for different strains while maintaining immunogenicity across multiple genotypes.
4Adaptability or versatility
If the vaccine uses conserved backbone sequences from multiple strains, then cross-strain protection is achieved, but the antigenic variation among strains may reduce immune recognition
Solution Approach 1:
The vaccine design optimizes the parameters of the capsid protein backbone by selecting specific conserved regions that maintain optimal immunogenicity while providing cross-strain recognition. The backbone sequences are engineered to preserve critical structural features and epitope conformation that are recognized by neutralizing antibodies, while minimizing regions prone to antigenic drift.
Data Source
AI summary
The present invention provides methods and compositions comprising a chimeric norovirus capsid protein comprising a norovirus VP1 major capsid protein backbone comprising a norovirus epitope selected from the group consisting of: a) Epitope A; b) Epitope B; c) Epitope C; d) Epitope D; e) Epitope E; f) Epitope F; and g) any combination of (a) through (f) above, wherein the norovirus epitope is from a norovirus strain that is different from the norovirus VP1 major capsid protein backbone.